Pre-treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 2085-2103

  Laios, Alexandros ^a,b   Mohamed, Bashir M ^c   Kelly, Lynne ^a   Flavin, Richard ^b   Finn, Stephen ^b   McEvoy, Lynda ^a,b   Gallagher, Michael ^b   Martin, Cara ^b   Sheils, Orla ^b   Ring, Martina ^b   Davies, Anthony ^c   Lawson, Margaret ^c   Gleeson, Noreen ^a   D'Arcy, T Tom ^a   d'Adhemar, Charles ^b   Norris, Lucy ^a   Langhe, Ream ^a,b   Saadeh, Feras Abu ^a   O'Leary, John J ^b   O'Toole, Sharon A ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Tallaght and Coombe Women's and Infant's University Hospital   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Chemoresistance; High content screening; mMP 9 MMP 2 inhibitor; Ovarian; Recurrent

Indexed keywords

2 [(4 BIPHENYLSULFONYL)AMINO] 3 PHENYLPROPIONIC ACID; CISPLATIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 2 INHIBITOR; MATRIX METALLOPROTEINASE 9 INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; PLATINUM COMPLEX; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; PROTEINASE INHIBITOR; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN; CELL STRAIN A2780; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; MONOTHERAPY; OVARY CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; TISSUE SECTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM PROTEINS; PROTEASE INHIBITORS;

EID: 84878641511     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14012085     Document Type: Article

References (43)

1. Vasey, P.A. Resistance to chemotherapy in advanced ovarian cancer: Mechanisms and current strategies. Br. J. Cancer 2003, 89, S23-S28.
2. Laios, A.; O'Toole, S.; Flavin, R.; Martin, C.; Ring, M.; Gleeson, N.; D'Arcy, T.; McGuinness, E.; Sheils, O.; Sheppard, B.; et al. An integrative model for recurrence in ovarian cancer. Mol. Cancer 2008, 7, 8-11.
3. Laios, A.; O'Toole, S.; Flavin, R.; Martin, C.; Kelly, L.; Ring, M.; Finn, S.; Barrett, C.; Loda, M.; Gleeson, N.; et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol. Cancer 2008, 7, doi:10.1186/1476-4598-7-35.
4. Overall, C.M.; Lopez-Otin, C. Strategies for mmp inhibition in cancer: Innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672.
5. Curran, S.; Murray, G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 1999, 189, 300-308.
6. Karakiulakis, G.; Papanikolaou, C.; Jankovic, S.M.; Aletras, A.; Papakonstantinou, E.; Vretou, E.; Mirtsou-Fidani, V. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 1997, 17, 158-168.
7. Zucker, S.; Lysik, R.M.; Zarrabi, M.H.; Moll, U. Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993, 53, 140-146.
8. Fishman, D.A.; Banionis, S.; Kearns, A.S.; Chilukuri, K.; Stack, M.S. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997, 80, 1457-1463.
9. Davidson, B.; Goldberg, I.; Gotlieb, W.; Kopolovic, J.; Ben-Baruch, G.; Nesland, J.; Berner, A.; Bryne, M.; Reich, R. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin. Exp. Metastasis 1999, 17, 799-808.
10. Alshenawy, H.A. Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths. Ann. Diagn. Pathol. 2010, 14, 387-395.
11. Kamat, A.A.; Fletcher, M.; Gruman, L.M.; Mueller, P.; Lopez, A.; Landen, C.N.; Han, L.; Gershenson, D.M.; Sood, A.K. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin. Cancer Res. 2006, 12, 1707-1714.
12. Schmalfeldt, B.; Prechtel, D.; Härting, K.; Späthe, K.; Rutke, S.; Konik, E.; Fridman, R.; Berger, U.; Schmitt, M.; Kuhn, W.; et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 2001, 7, 2396-2404.
13. Davidson, B. Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature. Anal. Cell Pathol. 2002, 23, 107-128.
14. Nemunaitis, J.; Poole, C.; Primrose, J.; Rosemurgy, A.; Malfetano, J.; Brown, P.; Berrington, A.; Cornish, A.; Lynch, K.; Rasmussen, H.; et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. 1998, 4, 1101-1109.
15. Coussens, L.M.; Fingleton, B.; Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer. J. Pathol. 2002, 189, 300-308.
16. Vogt, A.; Kalb, E.N.; Lazo, J.S. A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity. Oncol. Res. 2004, 14, 305-314.
17. 2 nanoparticles exposure as an early indicator of cytotoxicity. J. Nanobiotechnol. 2011, 9, doi:10.1186/1477-3155-9-29.
18. Byrne, F.; Prina-Mello, A.; Whelan, A.; Mohamed, B.M.;, Davies, A.; Gun'ko, Y.K.; Coey, J.M.D.; Volkov, Y. High content analysis of the biocompatibility of nickel nanowires. J. Magn. Magn. Mater. 2009, 321, 1341-1345.
19. Mohamed, B.M.; Verma, N.; Davies, A.M.; McGowan, M.; Staunton, K.C.; Prina-Mello, A.; Kelleher, D.; Botting, C.H.; Causey, C.P.; Thompson, P.R.; et al. Citrullination of proteins: A common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine 2012, 7, 1181-1195.
20. Mohamed, B.M.; Feighery, C.; Williams, Y.; Davies, A.; Kelleher, D.; Volkov, Y.; Kelly, J.; Abuzakouk, M. The use of Cellomics to study enterocyte cytoskeletal proteins in coeliac disease patients. Cent. Eur. J. Biol. 2008, 3, 258-267.
21. Zhou, X.; Wong, S. Informatics challenges of high-throughput microscopy. IEEE Signal Process. Mag. 2006, 23, 63-672.
22. Long, A.; Volkov, Y. High content analysis approach for targeted gene silencing and probing nanoscale cell responses. Eur. Pharm. Rev. 2009, 1, 22-30.
23. Hu, X.; Li, D.; Zhang, W.; Zhou, J.; Tang, B.; Li, L. Matrix metallopoteinase-9 expression correlates with poor prognosis and involved in ovarian cancer cell invasion. Arch. Gynecol. Obstet. 2012, 286, 1537-1543.
24. Kwon, Y.; Cukierman, E.; Godwin, A.K. Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumour cell matrix penetration/invasion. PLoS One 2011, 6, doi:10.1371/journal.pone.0018872.
25. Sharma, S.; Santiskulvog, C.; Bentolola, L.A.; Rao, J.; Dorigo, O.; Gimzewski, J.K. Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. Nanomedicine. 2012, 8, 757-766.
26. Zhang, W.; Yang, H.-C.; Wang, Q.; Yang, Z.-J.; Chen, H.; Wang, S.-M.; Pan, Z.-M.; Tang, B.-J.; Li, Q.Q.; Li, L. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res. 2011, 31, 3423-3428.
27. Gershtein, E.S.; Levkina, N.V.; Digayeva, M.A.; Laktionov, K.P.; Tereshkina, I.V.; Kushlinsky, N.E. Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms. Bull. Exp. Biol. Med. 2010, 149, 628-631.
28. Iizasa, T.; Fujisawa, T.; Suzuki, M.; Motohashi, S.-i.; Yasufuku, K.; Yasukawa, T.; Baba, M.; Shiba, M. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin. Cancer Res. 1999, 5, 149-153.
29. Devy, L.; Dransfield, D.T. New strategies for the next generation of matrix-metalloproteinase inhibitors: Selectively targeting membrane-anchored mmps with therapeutic antibodies. Biochem. Res. Int. 2011, 2011, doi:10.1155/2011/191670.
30. Lubbe, W.J.; Zhou, Z.Y.; Fu, W.; Zuzga, D.; Schulz, S.; Fridman, R.; Muschel, R.J.; Waldman, S.A.; Pitari, G.M. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin. Cancer Res. 2006, 12, 1876-1882.
31. Bond, M.; Murphy, G.; Bennett, M.R.; Amour, A.; Knäuper, V.; Newby, A.C.; Baker, A.H. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the n terminus. J. Biol. Chem. 2000, 275, 41358-41363.
32. Bendeck, M.P.; Irvin, C.; Reidy, M.A. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ. Res. 1996, 78, 38-43.
33. Southgate, K.M.; Davies, M.B.R.; Newby, A.C. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem. J. 1992, 288, 93-99.
34. Karam, A.K.; Santiskulvong, C.; Fekete, M.; Zabih, S.; Eng, C.; Dorigo, O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton 2010, 67, 535-544.
35. Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.; Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.; Kawada, K.; et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem. 1998, 41, 640-649.
36. Ikeda, M.; Maekawa, R.; Tanaka, H.; Matsumoto, M.; Takeda, Y.; Tamura, Y.; Nemori, R.; Yoshioka, T. Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: Application of film in situ zymography. Clin. Cancer Res. 2000, 6, 3290-3296.
37. Nyormoi, O.; Mills, L.; Bar-Eli, M. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ. 2003, 10, 558-569.
38. Rowinsky, E.K.; Humphrey, R.; Hammond, L.A.; Aylesworth, C.; Smetzer, L.; Hidalgo, M.; Morrow, M.; Smith, L.; Garner, A.; Sorensen, J.M.; et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor bay 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. 2000, 18, 178-186.
39. Kilian, M.; Gregor, J.I.; Heukamp, I.; Hanel, M.; Ahlgrimm, M.; Schimke, I.; Kristiansen, G.; Ommer, A.; Walz, M.K.; Jacobi, C.A.; et al. Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in bop-induced ductal pancreatic cancer in syrian hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75, 429-434.
40. Mohamed, B.; Feighery, C.; Kelly, J.; Coates, C.; O'Shea, U.; Barnes, L.; Abuzakouk, M. Increased protein expression of matrix metalloproteinases-1,-3, and-9 and TIMP-1 in patients with gluten-sensitive enteropathy. Dig. Dis. Sci. 2006, 51, 1862-1868.
41. Boehm, J.S.; Hahn, W.C. Understanding transformation: Progress and gaps. Curr. Opin. Genet. Dev. 2005, 15, 13-17.
42. Chou, T.-C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
43. Bliss, C. The toxicity of poisons applied jointly. Ann. Appl. Biol. 1939, 26, 585-615.